XML 17 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 23,693,633 $ 23,786,579
Short-term investments 57,538,852 103,638,844
Accounts receivable 3,316,361 6,003,205
Accounts receivable from affiliated entities 738,583 486,619
Prepaid expenses and other current assets 1,406,590 2,600,906
Prepaid expenses and other current assets from affiliated entities 1,120,805 1,846,007
Total current assets 87,814,824 138,362,160
Fixed assets, net 15,949,014 18,320,176
Investment in affiliated entity - GeneOne 6,381,926 9,069,401
Investment in affiliated entity - PLS 3,023,987 2,325,079
Intangible assets, net 4,760,145 6,009,729
Goodwill 10,513,371 10,513,371
Other assets 2,669,998 2,639,354
Total assets 131,113,265 187,239,270
Current liabilities:    
Accounts payable and accrued expenses 23,134,733 23,278,798
Accounts payable and accrued expenses due to affiliated entities 977,792 926,943
Accrued clinical trial expenses 5,671,764 8,611,892
Common stock warrants 0 360,795
Deferred revenue 223,577 1,175,353
Deferred revenue from affiliated entities 33,575 174,110
Deferred rent 1,065,387 877,535
Deferred grant funding 4,165,848 0
Deferred grant funding from affiliated entities 27,083 0
Total current liabilities 35,299,759 35,405,426
Deferred revenue, net of current portion 150,793 215,853
Deferred rent, net of current portion 8,518,207 9,104,416
Deferred tax liabilities 24,766 24,766
Other liabilities 87,333 0
Total liabilities 44,080,858 44,750,461
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 23 at December 31, 2018 and December 31, 2017 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2018 and December 31, 2017, issued and outstanding: 97,225,810 at December 31, 2018 and 90,357,644 at December 31, 2017 97,226 90,358
Additional paid-in capital 707,794,215 665,775,504
Accumulated deficit (620,426,436) (523,356,317)
Accumulated other comprehensive loss (528,867) (117,005)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 86,936,138 142,392,540
Non-controlling interest 96,269 96,269
Total stockholders’ equity 87,032,407 142,488,809
Total liabilities and stockholders’ equity $ 131,113,265 $ 187,239,270